The aim of this study is to assess the efficacy of varenicline compared to placebo in tobacco
dependent individuals who are undergoing concurrent treatment for alcohol dependence. As they
will be inpatients and under 24 hour medical care for the first 21 days of treatment, or
receiving outpatient treatment through the Alcohol Research and Treatment Clinic, this will
allow for a comprehensive assessment of the safety of varenicline in this population with
minimal risk of adverse consequences. The patients will continue their cessation treatment
for an additional 10 weeks as outpatients through the Nicotine Dependence Clinic at CAMH.
They will also be contacted at 6 months for follow-up.